Abstract
Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment with peginterferon/ribavirin. We studied the efficacy of BOC/PR in patients with prior treatment failure, including those with a null response (<2-log10 decline in HCV RNA), to peginterferon/ribavirin. Patients in the control arms of boceprevir Phase 2/3 studies who did not achieve SVR were re-treated with BOC/PR for up to 44 weeks. Patients enrolling >2 weeks after end-of-treatment in the prior study received PR for 4 weeks before adding boceprevir. Of 168 patients enrolled, four discontinued from the PR lead-in and 164 received BOC/PR. Baseline viral load was >800,000 IU/ml in 77% of patients; 62% had HCV genotype 1a, and 10% were cirrhotic. In the ITT analysis (all 168 patients), SVR was achieved in 20 (38%) of 52 patients with prior null response, 57 (67%) of 85 with prior partial response, and 27 (93%) of 29 with prior relapse. In the mITT analysis (164 BOC/PR-treated patients), SVR rates were 41% (20/49), 67% (57/85), and 96% (27/28), respectively. SVR was achieved by 48% of patients with <1-log10 decline in HCV-...Continue Reading
References
May 20, 2006·Gut·M ShermanUNKNOWN Canadian Pegasys Study Group
Jun 24, 2006·Journal of Viral Hepatitis·C BergG Cooksley
Feb 12, 2009·Gastroenterology·Thierry PoynardUNKNOWN Epic Study Group
Jul 25, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN IDEAL Study Team
Aug 10, 2010·Lancet·Paul Y KwoUNKNOWN SPRINT-1 investigators
Mar 1, 2011·Journal of Hepatology·Pierre DeltenrePhilippe Mathurin
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Oct 16, 2012·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Steven L FlammFred Poordad
Nov 28, 2012·Journal of Hepatology·Graham R FosterGaston Picchio
Mar 9, 2013·Gastroenterology·Jianmeng ChenDebra Birnkrant
Citations
Apr 15, 2014·The New England Journal of Medicine·Fred PoordadBarry Bernstein
Apr 8, 2014·Gastroenterology·Christophe HézodeUNKNOWN CUPIC Study Group
Nov 15, 2014·Scandinavian Journal of Gastroenterology·Etienne BrochotGilles Duverlie
Aug 29, 2014·PloS One·David F G MaloneJohan K Sandberg
Sep 7, 2016·PloS One·Floor A C BerdenWietske Kievit
Feb 28, 2017·Antiviral Research·Guangdi Li, Erik De Clercq
May 11, 2017·Medicine·Zhanyi LiZhixin Zhao
Jun 12, 2014·Expert Review of Clinical Pharmacology·Brian LamZobair Younossi
Oct 4, 2014·World Journal of Gastroenterology : WJG·Chiara RossoAntonina Smedile
Dec 4, 2014·World Journal of Gastroenterology : WJG·Veronica BernabucciErica Villa
Jan 12, 2016·PloS One·Heiner WedemeyerJames A Thommes
May 7, 2015·Current Opinion in Organ Transplantation·Bashar A Aqel, Hugo E Vargas
Jan 27, 2015·Alimentary Pharmacology & Therapeutics·Z M YounossiS C Gordon
Jun 5, 2015·Reviews in Medical Virology·Erik De Clercq
Dec 30, 2014·World Journal of Hepatology·Yo-Ichi IshidaHiroaki Kataoka
Jan 16, 2016·Clinical and Molecular Hepatology·Yuri ChoYoon Jun Kim
Aug 22, 2018·Immunological Reviews·Rubesh RajaNarendra M Dixit
May 24, 2014·Journal of Gastroenterology and Hepatology·Eric J Lawitz, Fernando E Membreno
Jul 1, 2015·Journal of Medical Virology·A ArainG Robaeys
Feb 3, 2015·Journal of Gastroenterology and Hepatology·Vince Fragomeli, Martin Weltman
Aug 1, 2015·World Journal of Gastroenterology : WJG·Wattana SukeepaisarnjaroenSeng Gee Lim
Nov 23, 2017·BioMed Research International·Zhanyi LiYutian Chong
Oct 15, 2014·Journal of Viral Hepatitis·S BrunoUNKNOWN Italian and Spanish (IAS)-BoC Study Group
Dec 3, 2014·Gastroenterology·Marc G Ghany, T Jake Liang
Sep 17, 2021·Archivum Immunologiae Et Therapiae Experimentalis·Bruno Rivas-SantiagoAdrian Rodriguez-Carlos